Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
| less than a minute read
This CD22 Approach Highlights the Importance of Experimental Medicine - and Collaboration
Get in touch
Get in touch
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
Get in touch
Get in touch
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-29-16-59-13-899-6abbee61460fb9469a25b973.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-10-21-12-53-31-969-6ad8b5cb057433a11d528afb.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-10-19-20-59-27-876-6ad684af780cfbe7accbf179.jpg)
